Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O G Ottmann

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
Annals of Hematology|April 1, 1996
Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherolA Ganser, A Maurer, C Contzen, et al.
Annals of Hematology|April 22, 1999
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factorW K Hofmann, A Ganser, G Seipelt, et al.
International Archives of Allergy and Applied Immunology|January 1, 1990
Histamine release from basophils after in vivo application of recombinant human interleukin-3 in manR D Merget, A B Maurer, U Koch, et al.
Histology and Histopathology|September 18, 2004
Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemiaJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
Clinical Pharmacology and Therapeutics|November 20, 2009
Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinibC Tanaka, O Q P Yin, V Sethuraman, et al.
BMC Cancer|July 9, 2016
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumorsN Haense, A Atmaca, C Pauligk, et al.
Leukemia|July 6, 2007
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemiaJ B Singer, Y Shou, F Giles, et al.
Leukemia|November 10, 2012
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemiaO G Ottmann, R A Larson, H M Kantarjian, et al.
Leukemia|July 29, 2017
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)G Bug, A Burchert, E-M Wagner, et al.
Blood|November 26, 1999
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemiaE Archimbaud, O G Ottmann, J A Yin, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
Annals of Hematology|April 1, 1996
Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherolA Ganser, A Maurer, C Contzen, et al.
Annals of Hematology|April 22, 1999
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factorW K Hofmann, A Ganser, G Seipelt, et al.
International Archives of Allergy and Applied Immunology|January 1, 1990
Histamine release from basophils after in vivo application of recombinant human interleukin-3 in manR D Merget, A B Maurer, U Koch, et al.
Histology and Histopathology|September 18, 2004
Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemiaJ Thiele, H M Kvasnicka, A Schmitt-Graeff, et al.
Clinical Pharmacology and Therapeutics|November 20, 2009
Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinibC Tanaka, O Q P Yin, V Sethuraman, et al.
BMC Cancer|July 9, 2016
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumorsN Haense, A Atmaca, C Pauligk, et al.
Leukemia|July 6, 2007
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemiaJ B Singer, Y Shou, F Giles, et al.
Leukemia|November 10, 2012
Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemiaO G Ottmann, R A Larson, H M Kantarjian, et al.
Leukemia|July 29, 2017
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)G Bug, A Burchert, E-M Wagner, et al.
Blood|November 26, 1999
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemiaE Archimbaud, O G Ottmann, J A Yin, et al.
Pageof 14